Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Spiliopoulou, Pavlina"" wg kryterium: Autor


Wyświetlanie 1-5 z 5
Tytuł:
Promising and Minimally Invasive Biomarkers: Targeting Melanoma.
Autorzy:
Spiliopoulou P; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.; School of Cancer Sciences, University of Glasgow, Glasgow G61 1BD, UK.
Holanda Lopes CD; Oncology Centre, Hospital Sírio-Libanês, São Paulo 05001-100, Brazil.
Spreafico A; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
Pokaż więcej
Źródło:
Cells [Cells] 2023 Dec 20; Vol. 13 (1). Date of Electronic Publication: 2023 Dec 20.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Melanoma*/genetics
Skin Neoplasms*/diagnosis
Skin Neoplasms*/genetics
Humans ; Biomarkers ; Biopsy ; Genomics
Czasopismo naukowe
Tytuł:
Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT).
Autorzy:
Genta S; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Lajkosz K; Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Yee NR; Toronto General Research Institute, University Health Network Toronto, Toronto, ON, Canada.
Spiliopoulou P; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Heirali A; Toronto General Research Institute, University Health Network Toronto, Toronto, ON, Canada.
Hansen AR; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Siu LL; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Saibil S; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Stayner LA; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Yanekina M; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Sauder MB; Division of Dematology, Department of Medicine, University of Toronto, Toronto, ON, Canada.
Keshavarzi S; Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Salawu A; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Vornicova O; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Butler MO; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Bedard PL; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Razak ARA; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Rottapel R; Department of Immunology, University of Toronto, Toronto, ON, Canada.
Chruscinski A; University Health Network, University of Toronto, Toronto, ON, Canada.
Coburn B; Toronto General Research Institute, University Health Network Toronto, Toronto, ON, Canada.
Spreafico A; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. .
Pokaż więcej
Źródło:
Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2023 Oct 21; Vol. 42 (1), pp. 276. Date of Electronic Publication: 2023 Oct 21.
Typ publikacji:
Journal Article
MeSH Terms:
Immune Checkpoint Inhibitors*/adverse effects
Autoantigens*
Humans ; Prospective Studies ; Immunoglobulin G ; Immunoglobulin M ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Remitting Seronegative Symmetrical Synovitis with Pitting Edema: A Case Report of an Immune-Related Adverse Event following Surgery.
Autorzy:
Janse van Rensburg HJ; Department of Internal Medicine, University of Toronto, Toronto, ON, Canada.
Spiliopoulou P; Department of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Makhzoum A; Department of Rheumatology, Trillium Health Partners, Mississauga, ON, Canada.
Healy BD; Department of Oncology, Juravinski Hospital and Cancer Centre, Hamilton Health Sciences, Hamilton, ON, Canada.
Pokaż więcej
Źródło:
Case reports in oncology [Case Rep Oncol] 2023 Aug 16; Vol. 16 (1), pp. 662-669. Date of Electronic Publication: 2023 Aug 16 (Print Publication: 2023).
Typ publikacji:
Case Reports
Raport
Tytuł:
Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers.
Autorzy:
Spiliopoulou P; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
Vornicova O; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.; Mount Sinai Hospital, University Health Network, Toronto, ON M5G 1X5, Canada.
Genta S; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
Spreafico A; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Jan 09; Vol. 24 (2). Date of Electronic Publication: 2023 Jan 09.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Melanoma*
Skin Neoplasms*/therapy
Humans ; Biomarkers, Tumor ; Immunotherapy/methods
Czasopismo naukowe
Tytuł:
A Case of Lenvatinib-Induced Focal Segmental Glomerulosclerosis (FSGS) in Metastatic Medullary Thyroid Cancer.
Autorzy:
Fleming K; Beatson West of Scotland Cancer Centre (BWoSCC), Glasgow, UK.
McGuinness J; Beatson West of Scotland Cancer Centre (BWoSCC), Glasgow, UK.
Kipgen D; Queen Elizabeth University Hospital, Glasgow, UK.
Glen H; Beatson West of Scotland Cancer Centre (BWoSCC), Glasgow, UK.
Spiliopoulou P; Beatson West of Scotland Cancer Centre (BWoSCC), Glasgow, UK.; Imperial College London, Hammersmith Hospital, London, UK.
Pokaż więcej
Źródło:
Case reports in oncological medicine [Case Rep Oncol Med] 2018 Oct 03; Vol. 2018, pp. 6927639. Date of Electronic Publication: 2018 Oct 03 (Print Publication: 2018).
Typ publikacji:
Case Reports
Raport
    Wyświetlanie 1-5 z 5

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies